Eurofins Scientific Tests Its Long-Term Support Ahead of Annual Results
Eurofins Scientific ended the session on Thursday, April 9 at €63.52, down 2.73% from the previous day. This decline occurred in a context of slight weakness in the CAC 40, which closed down 0.51% at 8,221.46 points, but the extent of the stock's drop significantly exceeded that of the Parisian index. The publication of the group's 2025 annual results, scheduled for tomorrow, Friday, April 10, is drawing attention.
Significant Drop Ahead of Annual Results
Eurofins Scientific's stock lost 2.73% this Thursday, closing at €63.52, a decline much greater than that of the SBF 120, which fell by 0.55% at the close. Over the last seven days, the stock has dropped 2.37%, and shows a decline of 7.76% over three months, despite a still largely positive annual performance of +34.78%. This downward movement comes on the eve of the publication of the 2025 annual results of the bioanalytical services specialist, scheduled for April 10. The general meeting is also scheduled for April 23. The tension observed in the markets, with a VIX at 25.78 points up by 6.66%, contributes to an environment of generalized caution.
Technical Analysis of the Stock
Technically, Eurofins Scientific's price is at €63.52, almost touching its 200-day moving average (€63.51), a level often considered as a medium-term support. However, the stock has significantly fallen below its 50-day moving average (€65.34), indicating a weakening of the short-term momentum. The RSI, at 55, remains in the neutral zone, signaling neither overbought nor oversold conditions. The Bollinger Bands place the price in the upper part of their channel (upper boundary at €66.03, lower boundary at €59.44), at 62% of the amplitude. The identified technical support is at €60.76, while the nearest resistance is positioned at €68.16. In the sector, Sanofi fell by 0.69% while UCB gained 0.75%, illustrating contrasting paths among life sciences stocks.
